---
title: "Krystal Biotech 2Q 2026: Revenue $119.22M, EPS $1.79— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294684198.md"
description: "Krystal Biotech reported Q2 2026 revenue of $119.22M and diluted EPS of $1.79, reflecting 24.1% YoY growth driven by VYJUVEK sales expansion in the EU and Japan. Net income rose 42.9% to $54.77M. The company maintains ~95% gross margins through manufacturing optimizations. R&D pipeline advances include completed Phase 3 enrollment for KB803 and progress on other programs."
datetime: "2026-08-03T11:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294684198.md)
  - [en](https://longbridge.com/en/news/294684198.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294684198.md)
generator: "portal-rs"
---

# Krystal Biotech 2Q 2026: Revenue $119.22M, EPS $1.79— 10-Q Summary

Krystal Biotech, Inc. reported second-quarter 2026 results with revenue of $119.22M and diluted EPS of $1.79, driven by continued VYJUVEK sales growth and expansion into new markets versus the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$119.22M

$96.04M

24.1%

Net income²

$54.77M

$38.33M

42.9%

Diluted EPS³

$1.79

$1.29

38.8%

*¹ Reported as “Product revenue, net”. ² Reported as “Net income”. ³ Reported as “Diluted income per common share”.*

**Business Highlights**

-   VYJUVEK net revenue for the quarter was $119.2M (YTD $235.6M), with growth driven by launches in the EU and Japan.
-   Market expansion continued: product launched in the U.S. (2023), Germany (Aug 2025), France and Japan (Oct 2025); U.K. approved May 2026; pricing discussions are ongoing.
-   High gross margins (approximately 95%) supported results; two in‑house commercial cGMP facilities and manufacturing optimizations reduced COGS per unit.
-   R&D pipeline advancing: KB803 Phase 3 enrollment complete and programs KB801, KB407 and KB707 progressing, alongside multiple FDA designations.

Original SEC Filing: Krystal Biotech, Inc. \[ KRYS \] - 10-Q - Aug. 03, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)

## Related News & Research

- [Is Krystal Biotech (KRYS) Cheap On Its Cantor Conference Spotlight?](https://longbridge.com/en/news/298945480.md)
- [Krystal Biotech CEO Krish S. Krishnan sells USD 7.59 million in common shares](https://longbridge.com/en/news/298080936.md)
- [Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing](https://longbridge.com/en/news/298728470.md)
- [abrdn Australia Equity Fund NAV at $10.63 as of Sept. 10, 2026](https://longbridge.com/en/news/298745554.md)
- [Acteos delays H1 2026 results release to Oct. 28](https://longbridge.com/en/news/298618428.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**